WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) announced today that New Jersey Governor Chris Christie was presented with its 2012 Governor of the Year award in recognition of his leadership and commitment to advancing biotechnology and promoting public health.

Governor Christie received the award in advance of next week's 2012 BIO International Convention in Boston, MA.

I am honored to be recognized by the Biotechnology Industry Organization, said Governor Christie. The key to economic recovery, both in our state and nationally, lies in securing economic growth and job creation in innovative industries such as the biotech sector. I'm proud that New Jersey continues to lead the way in this sector - creating the jobs and technology breakthroughs that improve the quality of life for our citizens and people around the world.

Governor Christie has been an exemplary leader in enhancing New Jerseys stature as one of the nations most vibrant biotech clusters through strong support for policies that benefit a pro-business and pro-biotechnology environment. His funding and support of biotech tax credits is a model for federal legislation that supports critical early-stage capital formation, said Jim Greenwood, President and CEO of BIO. The Governors leadership in this field will continue to benefit his state and region, in terms of jobs and innovation, for years to come.

From the moment he was inaugurated, Governor Christie has been a strong supporter of advancing biotechnology in New Jersey, and BioNJ is pleased to have nominated the Governor for this well deserved award, said Debbie Hart, President of BioNJ. In both word and deed, Governor Christie has worked to help our companies succeed as witnessed by his leadership in supporting the Technology Business Tax Certificate Transfer Program, the doubling of the R&D Tax Credit and naming of BioNJ to run the Life Sciences Talent Network.

Photos available upon request.

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Read more here:
New Jersey Governor Chris Christie Presented 2012 BIO Governor of the Year Award

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) will host a special China Day program dedicated to exploring questions about the changing landscape for innovation, healthcare reform, global regulatory trends and discuss the right ways to partner at the 2012 BIO International Convention in Boston, Mass.

The event will feature speakers with decades of experience conducting business in the Chinese life science sector. Panels will cover topics such as Healthcare Innovation in China, Developments in the IP Landscape in China, Global Trends in Biologics Regulations, Chinas Changing Market and Cross-Border Partnering in Biotechnology.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW,a multiblog platform and monthly newsletterthat aims to create an online biotech community where thethe industrycan connect to discuss the latest news. Subscribe to BIOtechNOW.

For more information: Visit http://www.bio.org Follow us on Twitter @IAmBiotech Join us on LinkedIn/MyBio Become a fan at facebook.com/IAmBiotech

The rest is here:
BIO to Host China Day: Biotechnology in the Middle Kingdom: A New Plan, A Renewed Focus, A One Billion Person Promise

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/rddx98/company_study_of_w) has announced the addition of the "Company Study of Walvax Biotechnology Co, Ltd.,2012" company profile to their offering.

Walvax Biotechnology Co, Ltd., founded in 2001, specializes in research & development, production and marketing of bio-pharmaceutical vaccines. In September 2010, it went public on the Shenzhen's Growth Enterprise Market (GEM), with the approval of China Securities Regulatory Commission (CSRC). Walvax Biotechnology employs about 863 people, including 161 for research and development. It has a new-type vaccine research & development center and pilot base at Kunming High-tech Industrial Development Zone (located in Kunming, Yunnan province) as well as vaccine production bases at Yuxi Hi-Tech & New Industrial Development Zone (located in Yuxi, Yunnan province) and Taizhou National Medical Hi-Tech Development Zone (located in Taizhou, Jiangsu province). In addition, its marketing network covers 30 provinces or cities and more than 2000 regions or counties throughout China

Key Topics Covered:

1 Profile

2 Operation

3 Revenue Structure

4 Gross Margin

5 Client and Supplier

6 R&D and Investment

See the article here:
Research and Markets: Company Study of Walvax Biotechnology Co, Ltd.,2012

ATLANTA, GA--(Marketwire -06/11/12)- GeoVax Labs, Inc. (GOVX) (GOVX), an Atlanta-based biotechnology firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, is attending the BIO International Convention taking place June 18-21 in Boston, MA at the Boston Convention & Exhibition Center, and will exhibit at Booth Number 1035 in the Georgia Pavilion. Exhibit hours are 12:00 pm - 5:00 pm on June 18, 10:00 am - 6:30 pm on June 19, 10:00 am to 5:00 pm on June 20 and 10:00 am to 1:00 pm on the final day, June 21.

GeoVax's President and CEO, Dr. Robert McNally, Board Chairman, David Dodd, and colleagues will be available to meet with interested parties either within the Georgia Pavilion or through the BIO partnering system to discuss the Company's preventive and therapeutic HIV/AIDS vaccine programs. In addition, Company executives anticipate meetings with the third party manufacturers of GeoVax's vaccines; with its contacts at analytical laboratories with which it is currently working; and with some of the Company's research partners.

About BIO

BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. For more information, please visit http://www.bio.org.

About GeoVax

GeoVax Labs, Inc. is a biotechnology company developing human vaccines for HIV (Human Immunodeficiency Virus - that leads to AIDS). GeoVax's HIV/AIDS vaccine technology is exclusively licensed from Emory University in Atlanta, GA, and is the subject of more than 20 issued or filed patent applications. GeoVax vaccines are designed for use in uninfected people to prevent acquisition of HIV-1 and limit the progression to AIDS should a person become infected. GeoVax vaccines are also being tested as a therapeutic treatment (for people already infected with the HIV-1 virus).

GeoVax's core vaccine technologies were developed by Dr. Harriet Robinson, Chief Scientific Officer, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institute of Allergy and Infectious Diseases (NIAID), the Centers for Disease Control and Prevention (CDC) and GeoVax. The technology uses recombinant DNA to prime the immune response and recombinant modified vaccinia Ankara (MVA) to boost the primed response. Both the DNA vaccine and the MVA vaccine express non-infectious virus-like-particles displaying the natural trimeric form of the HIV envelope protein.

GeoVax's vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. These trials have tested various combinations and doses of the DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety. Successful results from Phase 1 testing supported Phase 2 testing in an ongoing, fully enrolled, 299 participant trial in North and South America. The vaccine is also undergoing Phase 1/2 testing as a therapeutic in HIV-infected individuals.

Excerpt from:
GeoVax to Attend BIO International Convention June 18-21 in Boston

Background:
Phaeodactylum tricornutum is a unicellular diatom in the class Bacillariophyceae. The full genome has been sequenced (<30 Mb), and approximately 20 to 30% triacylglyceride (TAG) accumulation on a dry cell basis has been reported under different growth conditions. To elucidate P. tricornutum gene expression profiles during nutrient-deprivation and lipidaccumulation, cell cultures were grown with a nitrate to phosphate ratio of 20:1 (N:P) and whole-genome transcripts were monitored over time via RNA-sequence determination.
Results:
The specific Nile Red (NR) fluorescence (NR fluorescence per cell) increased over time; however, the increase in NR fluorescence was initiated before external nitrate was completely exhausted. Exogenous phosphate was depleted before nitrate, and these results indicated that the depletion of exogenous phosphate might be an early trigger for lipid accumulation that is magnified upon nitrate depletion. As expected, many of the genes associated with nitrate and phosphate utilization were up-expressed. The diatom-specific cyclins cyc7 and cyc10 were down-expressed during the nutrient-deplete state, and cyclin B1 was up-expressed during lipid-accumulation after growth cessation. While many of the genes associated with the C3 pathway for photosynthetic carbon reduction were not significantly altered, genes involved in a putative C4 pathway for photosynthetic carbon assimilation were up-expressed as the cells depleted nitrate, phosphate, and exogenous dissolved inorganic carbon (DIC) levels. P.tricornutum has multiple, putative carbonic anhydrases, but only two were significantly upexpressed (2-fold and 4-fold) at the last time point when exogenous DIC levels had increased after the cessation of growth. Alternative pathways that could utilize HCO3-were also suggested by the gene expression profiles (e.g., putative propionyl-CoA and methylmalonylCoA decarboxylases).
Conclusions:
The results indicate that P. tricornutum continued carbon dioxide reduction when population growth was arrested and different carbon-concentrating mechanisms were used dependent upon exogenous DIC levels. Based upon overall low gene expression levels for fatty acid synthesis, the results also suggest that the build-up of precursors to the acetyl-CoA carboxylases may play a more significant role in TAG synthesis rather than the actual enzyme levels of acetyl-CoA carboxylases per se. The presented insights into the types and timing of cellular responses to inorganic carbon will help maximize photoautotrophic carbonflow to lipid accumulation.Source:
http://www.biotechnologyforbiofuels.com/rss/

Background:
Presently, different studies are conducted related to the topic of biomass potential to generate through anaerobic fermentation process alternative fuels supposed to support the existing fossil fuel resources, which are more and more needed, in quantity, but also in quality of so called green energy. The present study focuses on depicting an optional way of capitalizing agricultural biomass residues using anaerobic fermentation in order to obtain biogas with satisfactory characteristics.. The research is based on wheat bran and a mix of damaged ground grains substrates for biogas production.
Results:
The information and conclusions delivered offer results covering the general characteristics of biomass used , the process parameters with direct impact over the biogas production (temperature regime, pH values) and the daily biogas production for each batch relative to the used material.
Conclusions:
All conclusions are based on processing of monitoring process results , with accent on temperature and pH influence on the daily biogas production for the two batches. The main conclusion underlines the fact that the mixture batch produces a larger quantity of biogas, using approximately the same process conditions and input, in comparison to alone analyzed probes, indicating thus a higher potential for the biogas production than the wheat bran substrate. Adrian Eugen Cioabla, Ioana Ionel, Gabriela-Alina Dumitrel and Francisc Popescu contributed equally to this work.Source:
http://www.biotechnologyforbiofuels.com/rss/

Background:
Renewable energy production is currently a major issue worldwide. Biogas is a promising renewable energy carrier as the technology of its production combines the elimination of organic waste with the formation of a versatile energy carrier, methane. In consequence of the complexity of the microbial communities and metabolic pathways involved the biotechnology of the microbiological process leading to biogas production is poorly understood. Metagenomic approaches are suitable means of addressing related questions. In the present work a novel high-throughput technique was tested for its benefits in resolving the functional and taxonomical complexity of such microbial consortia.
Results:
It was demonstrated that the extremely parallel SOLiDTM short-read DNA sequencing platform is capable of providing sufficient useful information to decipher the systematic and functional contexts within a biogas-producing community. Although this technology has not been employed to address such problems previously, the data obtained compare well with those from similar high-throughput approaches such as 454-pyrosequencing GS FLX or Titanium. The predominant microbes contributing to the decomposition of organic matter include members of the Eubacteria, class Clostridia, order Clostridiales, family Clostridiaceae. Bacteria belonging in other systematic groups contribute to the diversity of the microbial consortium. Archaea comprise a remarkably small minority in this community, given their crucial role in biogas production. Among the Archaea, the predominant order is the Methanomicrobiales and the most abundant species is Methanoculleus marisnigri. The Methanomicrobiales are hydrogenotrophic methanogens. Besides corroborating earlier findings on the significance of the contribution of the Clostridia to organic substrate decomposition, the results demonstrate the importance of the metabolism of hydrogen within the biogas producing microbial community.
Conclusions:
Both microbiological diversity and the regulatory role of the hydrogen metabolism appear to be the driving forces optimizing biogas-producing microbial communities. The findings may allow a rational design of these communities to promote greater efficacy in large-scale practical systems. The composition of an optimal biogas-producing consortium can be determined through the use of this approach, and this systematic methodology allows thedesign of the optimal microbial community structure for any biogas plant. In this way, metagenomic studies can contribute to significant progress in the efficacy and economic improvement of biogas production.Source:
http://www.biotechnologyforbiofuels.com/rss/

Scientific American to unveil the most comprehensive country-by-country comparison of biotechnology-innovation capacity at the BIO International Convention As athletes around the world prepare to travel to London for the 2012 Olympic Games, Scientific American gets set to unveil the worlds premiere performers in biotechnology through its 4th Annual Worldview Report and Scorecard.

This summer, more than 200 countries will parade their best of the best in the opening ceremonies in London, as Scientific American celebrates the leaders in biotechnology and, simultaneously, encourages countries seeking to expand their biotechnology-innovation capacity.

The parallels between the Olympics and biotechnology run even more deeply, including variations in rules around the world impacting performances. At the 1972 Munich games, for example, a last-minute rule change banned gold medal-favorite Bob Seagrens vaulting pole, forcing him to compete with unfamiliar equipment, although he still fought his way to a silver medal. Similarly, champions in biotechnology must find ways to perform under the pressure of shifting rules in different lands. For instance, some biotechnology crops can be planted in certain countries but not in others, and pharmaceutical regulators often talk about harmonization more than they achieve it. In the end, all players in the biotechnology industry could benefit from Seagrens never-give-up attitude.

As the world of biotechnology evolves, so does the Scientific American Worldview Scorecard. This year, 50 countries will be included in the index and there is a new metric that measures a countrys policy climate and stability. In addition, the protection of intellectual property (IP) and its impact on biotechnology innovation is explored in-depth. This years Scorecard also examines data in some new areas, including collaboration and medical tourism, which shows the interactive nature of a range of elements related to a countrys capabilities for encouraging biotechnology innovation.

Based on the past four years of data gathering, Scientific American can now start looking across time at trends in country scores and rankings, as well as the changing dynamics of the biotechnology industry since the economic crisis that started in 2007.

The Scientific American Worldview Report and Scorecard will use its four-year comparison of overall scores and country rankings to highlight the competitive nature of the biotechnology industry. In the past four years, Scientific American has added countries, incorporated new metrics and adjusted the methodology to improve the comparative power of this index. Despite the evolution of the Scorecards techniques, we can analyze the performance of countries over time to reveal some consistencies as well as some volatility, and explore ongoing trends by comparing results year-over-year.

Beyond the countries that climb our Scorecard podium, this years version places more emphasis than ever on the value of smaller companies and countries with less mature biotechnology industries. The breadth of this industry and its ongoing expansion makes it possible for a wide range of players to compete, especially ones who make the best of their inherent capabilities, such as natural resources, or team up with other players around the world.

Which country will win gold in greatest public company revenues? Which country will reign supreme for most public companies overall? Which country has the strongest patent protection? Attend the BIO International Convention Super Session, and find out by grabbing this years report.

Read more from the original source:
Going for the Biotechnology Gold

05-06-2012 21:47 Biotech Video

Follow this link:
Biotech Video: The Wonderful Wizarding World of Biotechnology - Video

Background:
For cellulosic biofuels processes, suitable characterization of the lignin remaining within the cell wall and correlation of quantified properties of lignin to cell wall polysaccharide enzymatic deconstruction is underrepresented in the literature. This is particularly true for grasses which represent a number of promising bioenergy feedstocks where quantification of grass lignins is particularly problematic due to the high fraction of p-ydroxycinnamates. The main focus of this work is to use grasses with a diverse range of lignin properties, and applying multiple lignin characterization platforms, attempt to correlate the differences in these lignin properties to the susceptibility to alkaline hydrogen peroxide (AHP) pretreatment and subsequent enzymatic deconstruction.
Results:
We were able to determine that the enzymatic hydrolysis of cellulose to to glucose (i.e.digestibility) of four grasses with relatively diverse lignin phenotypes could be correlated to total lignin content and the content of p-hydroxycinnamates, while S/G ratios did not appear to contribute to the enzymatic digestibility or delignification. The lignins of the brown midrib corn stovers tested were significantly more condensed than a typical commercial corn stover and a significant finding was that pretreatment with alkaline hydrogen peroxide increases the fraction of lignins involved in condensed linkages from 88-95% to ~99% for all the corn stovers tested, which is much more than has been reported in the literature for other pretreatments. This indicates significant scission of beta-O-4 bonds by retreatment and/or induction of lignin condensation reactions. The S/G ratios in grasses determined by analytical pyrolysis are significantly lower than values obtained using either thioacidolysis or 2DHSQC NMR due to presumed interference by ferulates.
Conclusions:
It was found that grass cell wall polysaccharide hydrolysis by cellulolytic enzymes for grasses exhibiting a diversity of lignin structures and compositions could be linked to quantifiable changes in the composition of the cell wall and properties of the lignin including apparent content of the p-hydroxycinnamates while the limitations of S/G estimation in grasses is highlighted.Source:
http://www.biotechnologyforbiofuels.com/rss/

NEW YORK, June 5, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Marine Biotechnology Industry

http://www.reportlinker.com/p080467/Global-Marine-Biotechnology-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biotechno

This report analyzes the Global markets for Marine Biotechnology in US$ Million by the following Product Segments: Marine Biomaterials, Marine Bioactive Substances, and Others. The major End-Use Applications analyzed are Industrial Products, Health Care/Biotechnology, Consumer Products, Public Services & Infrastructure, and Others. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for this market. The report profiles 87 companies including many key and niche players such as Aker BioMarine ASA, Ashland Inc., CP Kelco US, Inc., Cyanotech Corp., Elan Corp, FMC Corp., FMC Biopolymers AS, GlycoMar Ltd., Lonza Group Ltd., MariCal, Marinova, Mera Pharmaceuticals Inc., New England Biolabs Inc., PharmaMar S.A, PML Applications Ltd., Prolume Ltd., Royal DSM N.V, Sea Run Holdings Inc., and Tequesta Marine Biosciences. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

To order this report:

Biotechnology Industry: Global Marine Biotechnology Industry

More Market Research Report

Check our Industry Analysis and Insights

__________________________

Contact Nicolas: nicolasbombourg@reportlinker.com US: (805)-652-2626 Intl: +1 805-652-2626

Read the original:
Global Marine Biotechnology Industry

NEW YORK, June 5, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Biotechnology Reagents Industry

http://www.reportlinker.com/p098414/Global-Biotechnology-Reagents-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_

This report analyzes the worldwide markets for Biotechnology Reagents in US$ Million by the following Product Segments: Cell/Tissue Culture Reagents, DNA Sequencing/Synthesis Reagents, Electrophoresis Reagents, Flow Cytometry Reagents, Immunoassay Reagents, Liquid Chromatography Reagents, Polymerase Chain Reaction Reagents, and Protein Synthesis Reagents. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Latin America. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 267 companies including many key and niche players such as Abbott Diagnostics, Beckman Coulter, Inc., Becton Dickinson and Company, BioMrieux SA, EMD Biosciences, Inc., EMD Millipore Corporation, Fitzgerald Industries International, GE Healthcare, Life Technologies Corporation, Ortho-Clinical Diagnostics, PerkinElmer, Inc., Promega Corporation, Roche Diagnostics Ltd., Siemens Healthcare Diagnostics, Inc., and Sigma - Aldrich. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

To order this report:

In Vitro Diagnostic Industry: Global Biotechnology Reagents Industry

More Market Research Report

Check our Industry Analysis and Insights

__________________________

Contact Nicolas: nicolasbombourg@reportlinker.com

View post:
Global Biotechnology Reagents Industry

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Lando and Anastasi, LLP (L&A) today announced that Julie Gottselig, Dominic Yee, and Austin Kim have joined the firm.

The Cambridge-based intellectual property law firm, one of the largest IP firms in New England, continues its steady growth in response to strong client demand for high quality and responsive intellectual property legal services. The L&A biotechnology and pharmaceutical practice will expand with the addition of Julie Gottselig and Dominic Yee; and Austin Kim will join the firms electrical and computer science practice.

Julie Gottselig is an Associate at L&A. She focuses her practice on patent prosecution and counseling in the areas of biotechnology, pharmaceuticals, molecular biology, biochemistry, medical devices, and related fields. Prior to joining L&A, she was an Associate at McCarter & English, LLP in Boston. Julie is registered to practice before the United States Patent and Trademark Office.

Julie graduated from New England School of Law, summa cum laude, where she was the valedictorian of her class and recipient of the Dean Arthur W. MacLean Award for academic excellence. She received a Ph.D. in Neuroscience from the University of Iowa; she completed her post-doctoral fellowship at Harvard Medical School and Brigham & Womens Hospital; and she was a post-doctoral researcher at the Institute of Pharmacology & Toxicology, University of Zurich. Julie received her B.A. in Psychology from Colorado College. Prior to entering intellectual property law, Julie authored numerous peer-reviewed scientific research articles published in leading journals, and has received several research awards, including postdoctoral fellowship awards from the National Institute of Mental Health and the National Heart, Lung, and Blood Institute.

Dominic Yee is a Technology Specialist at L&A, and focuses his practice on patent prosecution, diligence and counseling in the areas of areas of biotechnology, pharmaceuticals, and chemistry.

Dominic received a Ph.D. in Chemistry from Columbia University, and he completed his post-doctoral fellowship with Nobel laureate Roger Tsien at the Howard Hughes Medical Institute at University of California San Diego (UCSD). Dominic received his B.S. in Chemistry and Biochemistry, magna cum laude, from UCSD. He attends Suffolk University Law School. Prior to entering intellectual property law, Dominic was a Scientist at Vertex Pharmaceuticals, where he worked on solid dosage form development and drug delivery technologies.

We are excited that Julie and Dominic have joined the life sciences team at L&A, and welcome the technological expertise they bring to both the biological and chemical aspects of our practice, commented Louis Myers, a Partner at the firm.

Austin Kim is an Associate at L&A. He focuses his practice on patent prosecution in the areas of computer science, electrical engineering, mechanical engineering, and medical devices. Prior to joining L&A, he was an Associate at Fish & Richardson in Boston. Austin is registered to practice before the United States Patent and Trademark Office.

Austin graduated from Boston College Law School. He received an M.Eng. and S.B. in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology.

Read more from the original source:
Lando & Anastasi, LLP Expands Biotechnology/Pharmaceutical and Electrical/Computer Patent Teams

NEW YORK, June 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Markets for Media, Sera and Reagents in Biotechnology -- Focus on Asia

http://www.reportlinker.com/p0870807/Global-Markets-for-Media-Sera-and-Reagents-in-Biotechnology----Focus-on-Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

INTRODUCTION

STUDY OBJECTIVES

BCC's goal in conducting this study is to provide an overview of the current and future characteristics of the global market for media, sera and the reagents used in biotechnology. The key objective is to present a comprehensive analysis of the current market and its future direction in the media, sera and biotechnology reagents markets as an important tool for the cell culture industry.

This report explores present and future strategies within the media and sera market, including reagents used in biotechnology. The improvisation of the market, the setbacks and the needs of the market are discussed in this report. The types of cell cultures and the products from cell culture technology are also presented in this report. The advantages and disadvantages for the use of various types of media are also covered in this report.

A detailed analysis of the cell culture industry structure has been conducted. This includes the biotechnology reagents, media and the sera used. Revenues are broken down by global region. Sales figures are estimated for the five-year period from 2011 through 2016.

Applications for the cell culture industrymedia, sera and reagents used in biotechnologyare also discussed in the report, with an emphasis on the usage in the research, production and contract segments. The report also covers significant patents in each segment.

REASONS FOR DOING THIS STUDY

The rest is here:
Global Markets for Media, Sera and Reagents in Biotechnology -- Focus on Asia

NEW YORK, June 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0870808/Global-Markets-for-Media-Sera-and-Reagents-in-Biotechnology----Focus-on-Emerging-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

INTRODUCTION

This report explores present and future strategies within the media and sera market, including reagents used in biotechnology. The improvisation of the market, the setbacks and the needs of the market are discussed in this report. The types of cell cultures and the products from cell culture technology are also presented in this report. The advantages and disadvantages for the use of various types of media are also covered in this report.

A detailed analysis of the cell culture industry structure has been conducted. This includes the biotechnology reagents, media and the sera used. Revenues are broken down by global region. Sales figures are estimated for the five-year period from 2011 through 2016.

Applications for the cell culture industrymedia, sera and reagents used in biotechnologyare also discussed in the report, with an emphasis on the usage in the research, production and contract segments. The report also covers significant patents in each segment.

REASONS FOR DOING THIS STUDY

Demand for cell culture products, namely media, sera and reagents, is increasing, with the increasing demand for biopharmaceuticals. Cell culture, a crucial component of the life sciences industry, has witnessed major development during the past three decades. R&D spending, along with increasing competition, patent expiries, new technologies and an international marketplace are moving the cell culture process in a new direction. As cell culture technologies evolved, a number of disciplines such as cell biology, genetic engineering, protein chemistry, genomics and chemical engineering have been successfully incorporated into the cell culture field.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of the different types of media used in light of the new technologies, growing competition and changing customer needs.

The lead consultant for this project was Dr. Kapil A. Setia, who holds a doctoral degree in the life sciences. She has a number of research publications to her credit.

Continued here:
Global Markets for Media, Sera and Reagents in Biotechnology -- Focus on Emerging Markets

PLANTATION, Fla. and HOUSTON, June 4, 2012 /PRNewswire/ --Goodwin Biotechnology, Inc. (GBI) and The University of Texas MD Anderson Cancer Center jointly announce a collaboration for process development and GMP manufacturing of a fusion protein composed of a vascular endothelial growth factor (VEGF) and the recombinant toxin, Gelonin (rGel), conjugated to a DOTA chelator. The fusion protein targets the tumor neovasculature, or blood supply, and inhibits tumor growth, and the DOTA chelator facilitates the subsequent labeling with a radioisotope for diagnostic imaging and/or therapeutics.

GBI has completed process development and is readying for the GMP manufacture of the drug conjugate. The GMP manufactured drug conjugate will subsequently be radiolabeled with 64Cu and evaluated in an early stage, human clinical trial.

"Contributing to such a medical advance is exciting," noted Muctarr Sesay, PhD, Vice President of Process Development at GBI. "We have a long history of collaborating with Dr. Rosenblum and MD Anderson for GMP manufacturing of therapeutic antibody : drug conjugates that have been used in human clinical trials. With the current project, we are also leveraging our extensive experience with preparing conjugates for subsequent radioisotope labeling to develop this important product for diagnostic and therapeutic applications."

"I have worked with GBI for over 10 years producing antibody : drug conjugates, and have been impressed with their bioconjugation expertise and the service they provide," noted Michael G. Rosenblum, Ph.D. Professor of Medicine; Head, Immunopharmacology and Targeted Therapy Laboratory and Director of Research Development in the Department of Experimental Therapeutics at MD Anderson. "The conjugate we are developing will hopefully enhance our ability to detect and treat primary cancers sooner, but it may also more accurately identify and inhibit metastatic spread earlier in the course of the disease."

About Goodwin Biotechnology, Inc. Goodwin Biotechnology is a fully integrated cGMP contract manufacturer of monoclonal antibodies, recombinant proteins and vaccines. GBI has the expertise and experience in cell line development, process development and GMP manufacturing of recombinant proteins and antibodies, as well as conjugated therapeutic proteins (e.g., antibodies conjugated to linkers for radioimmune therapy and diagnostics, other antibodies, proteins, chemotoxins, or plant toxins) by leveraging our proprietary conjugation technology. By working with GBI, our clients can enhance the value of their product candidates with clear development and manufacturing strategies and a road map to meet product requirements from the milligram, gram and kilogram range as the product candidates move along the clinical approval pathway. With nearly 20 years of experience as an independent contract manufacturer, GBI has worked with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established biopharmaceutical companies. For more information, please visit http://www.goodwinbio.com/.

For more information on the University of Texas M.D. Anderson Cancer Center, please visit http://www.mdanderson.org/

For more information, please contact:

Goodwin Biotechnology:

Dave Cunningham

Director of Marketing

The rest is here:
Goodwin Biotechnology and MD Anderson Cancer Center Collaborate on the GMP Manufacturing of a Fusion Protein Conjugate ...

Background:
Switchgrass is one of the most promising bioenergy crop candidates for the US. It gives relatively high biomass yield and can grow on marginal lands. However, its yields vary from year to year and from location to location. Thus it is imperative to develop a low input and sustainable switchgrass feedstock production system. One of the most feasible ways to increase biomass yields is to harness benefits of microbial endophytes.
Results:
We demonstrate that one of the most studied plant growth promoting bacterial endophytes, Burkholderia phytofirmans strain PsJN, is able to colonize and significantly promote the growth of switchgrass cv. Alamo under in vitro, growth chamber, and greenhouse conditions. In several in vitro experiments, the average fresh weight of PsJN-inoculated plants was approximately 50% higher than non-inoculated plants. When one-month-old seedlings were grown in a growth chamber for 30 days, the PsJN-inoculated Alamo plants had significantly higher shoot and root biomass compared to controls. Biomass yield (dry weight) averaged from five experiments was 54.1% higher in the inoculated treatment compared to noninoculated control. Similar results were obtained in greenhouse experiments with transplants grown in 4-gallon pots for two months. The inoculated plants exhibited more early tillers and persistent growth vigor with 48.6% higher biomass than controls. We also found that PsJN could significantly promote growth of switchgrass cv. Alamo under sub-optimal conditions. However, PsJN-mediated growth promotion in switchgrass is genotype specific.
Conclusions:
Our results show B. phytofirmans strain PsJN significantly promotes growth of switchgrass cv. Alamo under different conditions, especially in the early growth stages leading to enhanced production of tillers. This phenomenon may benefit switchgrass establishment in the first year. Moreover, PsJN significantly stimulated growth of switchgrass cv. Alamo under sub-optimal conditions, indicating that the use of the beneficial bacterial endophytes may boost switchgrass growth on marginal lands and significantly contribute to the development of low input and sustainable feedstock production system.Source:
http://www.biotechnologyforbiofuels.com/rss/

MENLO PARK, Calif.--(BUSINESS WIRE)--

Optivia Biotechnology Inc., a leader in transporter sciences and in vitro transporter assay services, proudly announces that it has received the 2012 CRO Leadership Award from Life Science Leader Magazine, winning Productivity, Reliability, Regulatory and Accessibility award categories.

Life Science Leader Magazine based the awards upon extensive customer surveys and in-depth interviews of more than 2600 outsourcing-facing biopharmaceutical executives, that were independently conducted by Nice Insight on a quarterly basis to assess the relative qualities of over 100 CROs.

Optivia is honored to receive this award as a validation of our leadership in the increasingly important field of Transporter Sciences, said Yong Huang, Ph.D., president and Chief Executive Officer of Optivia Biotechnology, Optivia has strived to deliver innovation, quality assay service and uncompromised customer support in meeting client needs. It is extremely gratifying that our efforts have been recognized by members of the biopharmaceutical industry we serve.

Optivia is the right company at the right time, added Dominique Bridon, Ph.D., Executive Vice President and Chief Operating Officer of Optivia, The field of transporter sciences is rapidly growing in light of increasing recognition of its utility in multiple aspects of drug discovery and development, especially in accessing drug-drug interactions (DDI) as evidenced by the recent FDA DDI Guidance (draft).

Optivia will continue to invest in innovation and business practice, delivering clients best-in-class assay services, value-added solution and remarkable client experience," Dr. Huang added.

About Transporter Sciences

Transporter sciences study membrane transporter proteins and their roles in (patho)physiology and pharmacology. Transporters are a class of 300 to 400 membrane proteins that act as natures gatekeepers, regulating trafficking of important endogenous substances and drugs in the body. As such, transporters not only play a vital role in drug response and safety, they can be pursued as therapeutic targets for various diseases.

About Optivia Biotechnology

Based in Menlo Park, CA, Optivia Biotechnology, Inc. is a leader in transporter research and transporter assay services. Optivia develops and provides an array of transporter assays, database and models to help in the discovery and development of drugs with improved safety and efficacy. For more information, visit http://www.optiviabio.com

View original post here:
Optivia Wins CRO Leadership Award from Life Science Leader

LOS ANGELES--(BUSINESS WIRE)--

Puma Biotechnology, Inc. (PBYI), a development stage biopharmaceutical company, announced that results from an ongoing Phase I clinical trial of its lead drug candidate PB272 (neratinib) given in combination with the anticancer drugs paclitaxel and trastuzumab in patients with metastatic HER-2 positive breast cancer were presented in a poster presentation at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting. This trial was sponsored by the National Surgical Adjuvant Breast and Bowel Project (NSABP), a clinical trials cooperative group supported by the National Cancer Institute (NCI).

A phase I dose-escalating study evaluating weekly paclitaxel with neratinib and trastuzumab in women with metastatic HER-2 positive breast cancer, NSABP FB-8.

The goal of the Phase I clinical trial was to determine the maximum tolerated dose of PB272 that could be given in combination with paclitaxel and trastuzumab to patients with metastatic HER-2 positive breast cancer. The study enrolled patients with confirmed HER-2 positive metastatic or locally advanced breast cancer, and documented disease progression following prior treatment with trastuzumab and taxane chemotherapy. Patients were administered PB272 at doses of 120 mg, 160 mg, 200 mg or 240 mg per day, respectively, in combination with paclitaxel given intravenously at a dose of 80 mg/m2 on days 1, 8, and 15 of every 28 day cycle until disease progression and trastuzumab administered intravenously weekly using a 4 mg/kg loading dose, then 2 mg/kg weekly until disease progression.

The results of the study showed that of the 120 mg PB272 dose group, 1 of 3 patients developed a dose limiting toxicity (DLT) consisting of grade 3 diarrhea. Three additional patients were enrolled and none experienced DLT. At PB272 dose levels of 160 mg and 200 mg, there were no DLTs. At the PB272 240 mg dose level, 2 of 3 patients had DLTs involving grade 3 diarrhea. The efficacy results from the trial showed that for the 15 evaluable patients, 8 patients showed clinical activity. This included 1 patient with a complete response (CR) as per the RECIST criteria; 1 patient with non-measurable metastatic disease (skin metastases) who demonstrated a complete resolution of disease; 4 patients with a partial response as per the RECIST criteria; and 2 patients with ongoing stable disease, of whom 1 has been ongoing for over 4 months and 1 has been ongoing for over 10 months.

Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology, said, "We are pleased to present the results of this Phase I trial at the ASCO Annual Meeting and to see such a strong indication of efficacy for PB272. In trials of other anti-HER tyrosine kinase inhibitors given in combination with paclitaxel and trastuzumab, the dose of the tyrosine kinase inhibitor needed to be greatly reduced, by as much as 50%, from the dose typically given as a single agent due to tolerability issues.

Based on the results of this trial it appears that we may be able to administer PB272, when it is given in combination with paclitaxel and trastuzumab, at doses very close to the dose typically used when PB272 is administered as a single agent. This could position the drug well against other anti-HER tyrosine kinase inhibitors in various settings, including the neoadjuvant setting. We look forward to continuing to study this combination as we continue to advance PB272 into further development in the HER-2 positive breast cancer population.

About Puma Biotechnology

Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.

Further information about Puma Biotechnology can be found at http://www.pumabiotechnology.com.

Read the rest here:
Puma Biotechnology Presents Positive PB272 Clinical Data at ASCO 2012 Annual Meeting

NEW YORK, May 31, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Markets for Media, Sera and Reagents in Biotechnology -- Focus on the U.S.

http://www.reportlinker.com/p0870805/Global-Markets-for-Media-Sera-and-Reagents-in-Biotechnology----Focus-on-the-US.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

INTRODUCTION

STUDY OBJECTIVES

BCC's goal in conducting this study is to provide an overview of the current and future characteristics of the global market for media, sera and the reagents used in biotechnology. The key objective is to present a comprehensive analysis of the current market and its future direction in the media, sera and biotechnology reagents markets as an important tool for the cell culture industry.

This report explores present and future strategies within the media and sera market, including reagents used in biotechnology. The improvisation of the market, the setbacks and the needs of the market are discussed in this report. The types of cell cultures and the products from cell culture technology are also presented in this report. The advantages and disadvantages for the use of various types of media are also covered in this report.

A detailed analysis of the cell culture industry structure has been conducted. This includes the biotechnology reagents, media and the sera used. Revenues are broken down by global region. Sales figures are estimated for the five-year period from 2011 through 2016.

Applications for the cell culture industrymedia, sera and reagents used in biotechnologyare also discussed in the report, with an emphasis on the usage in the research, production and contract segments. The report also covers significant patents in each segment.

REASONS FOR DOING THIS STUDY

Go here to see the original:
Global Markets for Media, Sera and Reagents in Biotechnology -- Focus on the U.S.